ABSTRACT
AIM: A multicentre, randomized, placebo-controlled double-masked study was conducted to assess the efficacy and safety of Rimexolone 1% eye drops in reducing inflammation after cataract surgery and intra-ocular lens implantation. METHODS: Rimexolone 1% (124 patients) or placebo (58 patients) was given, four times a day for 14 days starting 22-34 hours after surgery. All patients also received tobramycin 0.3% four times a day for 7 days. The clinical signs of ocular inflammation were recorded on days 1, 3, 8, 15 and 17 or 18. RESULTS: Rimexolone 1% markedly decreased the mean inflammation severity scores, and the sum of clinical assessments of cells and flare in the anterior chamber compared with placebo at each assessment. In addition, the percentage of patients with no anterior chamber inflammation was significantly higher with Rimexolone 1% than with the placebo at each assessment. All these results were statistically significant. Intra-ocular pressure did not rise after treatment with Rimexolone 1%. CONCLUSIONS: The results suggest that Rimexolone 1% ophthalmic solution is an effective and safe steroidal anti-inflammatory agent for topical use following cataract surgery and intra-ocular lens implantation.
Subject(s)
Anti-Inflammatory Agents/therapeutic use , Cataract Extraction/adverse effects , Endophthalmitis/drug therapy , Postoperative Complications/drug therapy , Pregnadienes/therapeutic use , Adult , Aged , Aged, 80 and over , Anti-Bacterial Agents/administration & dosage , Anti-Bacterial Agents/therapeutic use , Anti-Inflammatory Agents/administration & dosage , Double-Blind Method , Drug Therapy, Combination , Endophthalmitis/etiology , Female , Follow-Up Studies , Humans , Lens Implantation, Intraocular/adverse effects , Male , Middle Aged , Ophthalmic Solutions , Pregnadienes/administration & dosage , Safety , Tobramycin/administration & dosage , Tobramycin/therapeutic use , Treatment OutcomeABSTRACT
An ultrasonically driven needle placed into the body of the nucleus, with subsequent injection of balanced salt solution (BSS), can be used to fragment the nucleus into sections or lamellae that can potentially be emulsified with greater ease and less ultrasound energy delivered to the eye. This separation of the nucleus has been designated hydrodelineation. The six surgeons participating in this study subjectively reported that the use of hydrodelineation facilitated phacoemulsification, on average, in 91% of their cases. Review of study data indicated that significantly less ultrasound time and cumulative displayed energy were noted in phacoemulsification of grade 2+ and 3+ cataracts after hydrodelineation than in cases in which hydrodelineation was not performed. The results in cases performed with and without hydrodelineation were statistically equivalent in complications and postoperative patient outcomes.
Subject(s)
Cataract Extraction/methods , Cataract/physiopathology , Lens Nucleus, Crystalline/physiopathology , Ultrasonic Therapy/instrumentation , Cataract Extraction/instrumentation , Follow-Up Studies , Humans , Postoperative Complications , Preoperative Care , Surgical Instruments , Treatment OutcomeABSTRACT
We review the main physical parameters involved in YAG laser surgery upon transparent ocular media, as well as the plasma creation process. Then we study the variations of the retinal illumination due to laser fluctuations, leading to some conclusions about safety.
